Back to search
FDAFDA · Food and drugs·Recall number D-0558-2025

Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Published August 13, 2025 · Recall initiated: July 18, 2025

Summary

FDA records drug Class II recall D-0558-2025, published August 13, 2025 and initiated July 18, 2025. Recalling firm: AEQUITA PHARMACY; Status: Ongoing; Reported quantity: 146 vials; Lot: All Lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Processing Controls.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AEQUITA PHARMACY
Distributor
MA
Lot
All Lots within expiry.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. recalled?

Yes. FDA published recall D-0558-2025 on August 13, 2025. Reported hazard: Lack of Processing Controls.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail